Lymphoma & Myeloma 2011


Lymphoma & Myeloma 2011: An International Congress on Hematologic Malignancies took place October 20-22, 2011, in New York, New York.


Doc advises against rituximab maintenance in FL

Mark Fuerst Read Article
Published: 11/02/11

Follicular lymphoma cells

Most patients with follicular lymphoma (FL) should not receive rituximab maintenance therapy, said a lymphoma expert at Lymphoma & Myeloma 2011. Before rituximab maintenance can be accepted in FL, clinicians need to know the optimal maintenance regimen or duration, the effect on overall survival, the impact on subsequent therapy, its role relative to retreatment, and the long-term toxicities, said Bruce Cheson, MD, of Georgetown University Hospital in Washington, DC. [Read Article]

Watch and wait: Not passé in asymptomatic FL

Mark Fuerst Read Article
Published: 10/31/11

FL in the spleen

A watch-and-wait approach should not be considered passé in the treatment of asymptomatic follicular lymphoma (FL), according to a speaker at Lymphoma & Myeloma 2011. The majority of FL patients present with asymptomatic, advanced-stage disease. The accepted and long-honored practice has been watchful waiting, because standard chemotherapy with single or multiple agents did not change the relapsing nature of the disease or overall survival rates. [Read Article]

Experts debate maintenance in MM

Erilyn Riley Read Article
Published: 10/28/11

David H. Vesole, MD, PhD (left)
and Antonio Palumbo, MD

Asserting that maintenance therapy is important for all patients, Antonio Palumbo, MD, from the University of Torino in Italy, firmly supported the necessity of maintenance therapy in multiple myeloma (MM). David H. Vesole, MD, PhD, from Hackensack University Medical Center in New Jersey, staunchly supported the position that maintenance therapy is not necessary, arguing that the impressive results you see initially may be misleading. They faced off at Lymphoma & Myeloma 2011 . . . [Read Article]

Speaker discourages denosumab for MM

Erilyn Riley Read Article
Published: 10/27/11

Berenson, James R. MD.jpg
James R. Berenson, MD

Despite efficacy that makes denosumab comparable to zoledronic acid in preventing skeletal-related events (SREs), it should not be used in multiple myeloma (MM) patients, according to a speaker at Lymphoma & Myeloma 2011, which was held recently in New York City. James E. Berenson, MD, of the Institute for Myeloma & Bone Cancer Research in Los Angeles, explained why he made this cautionary statement during his talk on managing bone-related disease in myeloma. [Read Article]


    {icon} {author} Read Article
    Published: {pubDate}